Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Liabilities and Shareholders Equity (2016 - 2026)

Biomerica's Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $4.9 million for Q1 2026.

  • Quarterly results put Liabilities and Shareholders Equity at $4.9 million for Q1 2026, down 33.87% from a year ago — trailing twelve months through Feb 2026 was $23.7 million (down 25.38% YoY), and the annual figure for FY2025 was $5.9 million, down 35.76%.
  • Liabilities and Shareholders Equity for Q1 2026 was $4.9 million at Biomerica, down from $6.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $17.6 million in Q1 2022 to a low of $4.9 million in Q1 2026.
  • The 5-year median for Liabilities and Shareholders Equity is $9.3 million (2024), against an average of $9.6 million.
  • The sharpest move saw Liabilities and Shareholders Equity soared 31.56% in 2022, then tumbled 53.25% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $9.9 million in 2022, then grew by 19.41% to $11.8 million in 2023, then crashed by 38.52% to $7.3 million in 2024, then dropped by 17.05% to $6.0 million in 2025, then fell by 19.16% to $4.9 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $4.9 million, $6.0 million, and $6.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.